Model Development and Prospective Validation to Predict the Response to Neoadjuvant Chemotherapy in Cervical Cancer
Cervical cancer is one of the major health problems for chinese women. Besides surgery and radiotherapy, neoadjuvant chemotherapy has been proved to be an effective program by many studies.
However, not all patients respond well to neoadjuvant chemotherapy. Knowing the therapeutic effect of the neoadjuvant chemotherapy before receiving it can not only reduce the economic burden, but also more importantly save time to take more suitable treatments.
This study is undertaken to build a model combine both clinical and genetic factors to predict the effects of neoadjuvant chemotherapy.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Model Development and Prospective Validation to Predict the Response to Neoadjuvant Chemotherapy in Cervical Cancer|
- The clinical and pathological response to neoadjuvant chemotherapy [ Time Frame: 1 to 3 months ] [ Designated as safety issue: Yes ]including: ① clinical response（tumor size）, ②pathological response（<3 mm or not）, ③toxic response (degree) and so on.
- long-term response for patients undergoing neoadjuvant chemotherapy [ Time Frame: up to 10 years to 20 years or more ] [ Designated as safety issue: Yes ]including ① DFS, ②OS, ③long-term complications，④secondary diseases, ⑤life quality, ⑥long-term toxic effects caused by the treatment and so on.
Biospecimen Retention: Samples With DNA
|Estimated Study Completion Date:||December 2023|
|Estimated Primary Completion Date:||December 2018 (Final data collection date for primary outcome measure)|
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01628757
|Contact: Ma Ding, M.D.||email@example.com|
|Wuhan, Hubei, China, 430030|
|Contact: Ma Ding, M.D. 86-27-8362681 firstname.lastname@example.org|